@ajwomble4's Wegovy week 4 update, fact-checked

What does this TikTok actually claim?

@ajwomble4 shares her week 4 experience with Wegovy at 0.25mg, the standard starting dose. Her hashtags mention insulin resistance and prediabetes, suggesting she's using the medication for metabolic health.

Without seeing the video content, we can't evaluate specific weight loss claims or side effects she might report. However, her timing and dosage align with standard Wegovy protocols, which start patients at 0.25mg weekly before gradually increasing to the full 2.4mg dose over 16-20 weeks.

Is week 4 at 0.25mg when you'd see real results?

Probably not much yet, and that's completely normal. The 0.25mg starting dose exists primarily for tolerability, not efficacy.

The STEP 1 trial (Wilding et al., NEJM, 2021) showed most weight loss occurred after patients reached higher doses. At 0.25mg, semaglutide's appetite suppression is minimal compared to the therapeutic 2.4mg dose. Some people report early nausea or reduced hunger, but dramatic changes at week 4 would be unusual.

The trial's weight loss curve was gradual. Patients lost about 5.9% of body weight by week 20, reaching 14.9% loss by week 68 on the full dose.

Are her hashtags about insulin resistance accurate?

Semaglutide does improve insulin sensitivity, though it's not FDA-approved specifically for insulin resistance. The mechanism makes sense: GLP-1 receptor agonists enhance glucose-dependent insulin secretion and slow gastric emptying.

The STEP 2 trial (Davies et al., Lancet, 2021) specifically studied people with type 2 diabetes. Participants saw HbA1c reductions of 1.6% alongside 9.6% weight loss at 68 weeks. However, this study used diabetic patients, not just those with insulin resistance or prediabetes.

For prediabetes specifically, the evidence is more limited. Weight loss itself improves insulin sensitivity, so it's hard to separate semaglutide's direct metabolic effects from its weight loss benefits.

What's misleading about week 4 updates?

Early progress reports can set unrealistic expectations. Most people won't see dramatic changes at 0.25mg, and that's fine.

The bigger issue is that social media updates rarely mention the full picture. Semaglutide requires 16-20 weeks to reach full dose, and the STEP trials measured outcomes at 68 weeks. Quick updates don't capture the gradual, long-term nature of this treatment.

Also, individual responses vary widely. Some people lose weight quickly even on low doses, while others need months at 2.4mg to see significant changes. Week 4 snapshots don't predict final outcomes.

What should you actually know about starting Wegovy?

The first month is about building tolerance, not seeing dramatic results. Nausea affects 44% of patients in clinical trials, usually improving as your body adjusts.

Real weight loss typically starts around week 8-12 as doses increase. The STEP 1 trial showed 5% weight loss by week 20, with continued improvement throughout the 68-week study period. Patience is required.

If you're considering Wegovy for prediabetes or insulin resistance, discuss realistic timelines with your doctor. The medication works, but it's a marathon, not a sprint. Week 4 updates make good social media content but don't reflect the full treatment journey.